[123I]FP-CIT SPET Imaging in Drug-Induced Parkinsonism

被引：38

作者：

Tinazzi, Michele ^{[2
,3
]}

Ottaviani, Sarah ^{[3
]}

Isaias, Ioannis U. ^{[1
]}

Pasquin, Isabella ^{[4
]}

Steinmayr, Maria ^{[5
]}

Vampini, Claudio ^{[5
]}

Pilleri, Manuela ^{[6
]}

Moretto, Giuseppe ^{[3
]}

Fiaschi, Antonio ^{[2
]}

Smania, Nicola ^{[2
]}

Giorgetti, Piergiorgio ^{[4
]}

Antonini, Angelo ^{[1
]}

机构：

[1] Univ Milan, Parkinson Inst, Ist Clin Perfez Amento, I-20126 Milan, Italy

[2] Univ Verona, Dipartimento Sci Neurol & Vis, I-37100 Verona, Italy

[3] Unita Operat Neurol OC Borgo Trento, Verona, Italy

[4] Unita Operat Med Nucl OC Borgo Trento, Verona, Italy

[5] Unita Operat Psichiatria OC Borgo Trento, Verona, Italy

[6] Ctr Parkinson Villa Margherita, Vicenza, Italy

来源：

MOVEMENT DISORDERS | 2008年 / 23卷 / 13期

关键词：

I-123]FP-CIT SPET; Parkinson's disease; drug-induced parkinsonism; dopamine transporter;

D O I：

10.1002/mds.22098

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

We assessed the status of dopamine nerve terminals in patients treated with dopamine receptor blocking agents (DRBAs) who had developed drug-induced parkinsonism (DIP). We performed [I-123]FP-CIT SPET in 32 consecutive patients who were on DRBAs for at least 6 months and developed extrapyramidal signs. The UPDRS-III was used to assess clinical severity. Twenty-six age- and sex-matched healthy subjects served as control group. Putamen [I-123]FP-CIT SPET binding was reduced in 14 and normal in the remaining 18 patients. There was no difference between the two group for age, duration of DRBAs treatment. UPDRS III, tremor, rigidity, and bradykinesia subscores for upper and lower limbs. Conversely, symmetry of parkinsonian signs and presence bucco-linguo-masticatory dyskinesias were more frequent in individuals with normal tracer binding. Imaging of the dopamine transporter may help to identify subjects with DIP secondary to a loss of dopamine nerve terminals. (C) 2008 Movement Disorder Society.

引用

页码：1825 / 1829

页数：5

共 28 条

[1] UNSUSPECTED, SURREPTITIOUS DRUG-INDUCED PARKINSONISM [J].